Here, prophylactic and therapeutic OM-MOG maintained or induced the alternative activation of myeloid cells even in the presence of strong pro-inflammatory stimuli provided by immune adjuvants and the EAE environment. The gene discussed is MOG; the disease is ocular melanoma.